Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$1.61
+2.23%
Mkt Cap $238.61M
Analyst Ratings
No recent rating data.
Price Target (5 analysts)
$6.50
Range $5.00 – $8.00
Implied Upside
+305.0%
Consensus $6.50 vs current $1.61
NASDAQ·Healthcare·Biotechnology
$1.61
+2.23%
Mkt Cap $238.61M
No recent rating data.
Price Target (5 analysts)
$6.50
Range $5.00 – $8.00
+305.0%
Consensus $6.50 vs current $1.61